In response to the uncertainty of which route is better for drug administration in Out-of-Hospital Cardiac Arrest (OHCA) ie., intraosseous (I/O) or intravenous (IV), “we conducted the PARAMEDIC-3 trial to determine the clinical effectiveness of an intraosseous-first strategy, as compared with an intravenous-first strategy, in adults with out-of- hospital cardiac arrest.”
The Study
Couper K et al. A Randomised Trial of Drug Route in Out-of-Hospital Cardiac Arrest. NEJM October 31st 2024(1)
Bottom Line
Survival at 30 days was 4.5% (137/3030) (I/O) vs 5.1% (155/3034) in IV group (adjusted odds ratio, 0.94; 95% confidence interval [CI], 0.68 to 1.32; P=0.74) ie., I/O did not increase 30 day survival over IV.
What They Did
This was an open label, pragmatic, randomised trial, conducted in the United Kingdom.
Inclusion Criteria:
